Back to today’s briefing

Story perspectives

Novo Nordisk’s Ozempic Boosts Walking Distance for PAD Patients

3/29/2025

31 5

Summary

Novo Nordisk's Breakthrough

Novo Nordisk's semaglutide, known as Ozempic and Wegovy, is transforming the lives of patients with type 2 diabetes and peripheral artery disease (PAD). The groundbreaking STRIDE trial demonstrated a remarkable 13% increase in maximum walking distance, significantly boosting patients' quality of life and filling a vital gap in PAD treatment.

Summary

Novo Nordisk's Advances

Novo Nordisk's diabetes pill, Rybelsus, has demonstrated a promising 14% reduction in cardiovascular risks during trials, potentially leading to broader approval. Meanwhile, in Egypt, Ozempic is gaining traction for weight loss, yet concerns about side effects and steep prices linger. The threat of counterfeit drugs adds to the urgency, prompting health officials to issue critical warnings.

1 of 2

Novo Nordisk's Breakthrough

Novo Nordisk's semaglutide, known as Ozempic and Wegovy, is transforming the lives of patients with type 2 diabetes and peripheral artery disease (PAD). The groundbreaking STRIDE trial demonstrated a remarkable 13% increase in maximum walking distance, significantly boosting patients' quality of life and filling a vital gap in PAD treatment.

1 / 2